Integra LifeSciences Holdings Cash Flow Conversion Efficiency
Integra LifeSciences Holdings cash flow conversion efficiency. Based on the latest financial reports, Integra LifeSciences Holdings (IART) has a cash flow conversion efficiency ratio of 0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.80 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Integra LifeSciences Holdings (1995–2025)
Cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2025. This chart illustrates how Integra LifeSciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Integra LifeSciences Holdings for real-time trading data and today's change.
Integra LifeSciences Holdings Cash Flow Conversion Ratio Explained
Integra LifeSciences Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Integra LifeSciences Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integra LifeSciences Holdings ranked by their cash flow conversion efficiency. Also see Integra LifeSciences Holdings market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bristow Group Inc
NYSE:VTOL
|
-0.008x |
|
E2E Networks Limited
NSE:E2E
|
0.020x |
|
Dis-Chem Pharmacies
JSE:DCP
|
0.341x |
|
Chengdu Yunda Technology Co Ltd
SHE:300440
|
0.004x |
|
Brighton-Best International Taiwan
TWO:8415
|
0.065x |
|
Bolsas y Mercados Argentinos SA
BA:BYMA
|
0.016x |
|
Wuhan East Lake High Technology Group Co Ltd
SHG:600133
|
-0.006x |
|
Air Global PLC Ordinary Shares
NASDAQ:AIIR
|
-0.069x |
Annual Cash Flow Conversion Efficiency for Integra LifeSciences Holdings (1995–2025)
The table below shows the annual cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2025. Review IART free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.04 Billion | $50.38 Million | 0.048x | -42.33% |
| 2024-12-31 | $1.55 Billion | $129.38 Million | 0.084x | -5.01% |
| 2023-12-31 | $1.59 Billion | $139.96 Million | 0.088x | -39.86% |
| 2022-12-31 | $1.80 Billion | $264.47 Million | 0.147x | -20.96% |
| 2021-12-31 | $1.68 Billion | $312.43 Million | 0.185x | +37.82% |
| 2020-12-31 | $1.51 Billion | $203.83 Million | 0.135x | -17.63% |
| 2019-12-31 | $1.42 Billion | $231.43 Million | 0.163x | +12.55% |
| 2018-12-31 | $1.38 Billion | $199.68 Million | 0.145x | +21.93% |
| 2017-12-31 | $962.31 Million | $114.54 Million | 0.119x | -14.14% |
| 2016-12-31 | $839.67 Million | $116.41 Million | 0.139x | +10.26% |
| 2015-12-31 | $751.44 Million | $94.48 Million | 0.126x | +11.45% |
| 2014-12-31 | $704.32 Million | $79.46 Million | 0.113x | +41.94% |
| 2013-12-31 | $670.18 Million | $53.27 Million | 0.079x | -29.91% |
| 2012-12-31 | $517.77 Million | $58.72 Million | 0.113x | -46.45% |
| 2011-12-31 | $492.64 Million | $104.33 Million | 0.212x | +0.29% |
| 2010-12-31 | $499.96 Million | $105.57 Million | 0.211x | -34.41% |
| 2009-12-31 | $444.88 Million | $143.24 Million | 0.322x | +55.33% |
| 2008-12-31 | $350.21 Million | $72.59 Million | 0.207x | +14.79% |
| 2007-12-31 | $260.43 Million | $47.03 Million | 0.181x | -25.42% |
| 2006-12-31 | $296.16 Million | $71.70 Million | 0.242x | +23.43% |
| 2005-12-31 | $289.82 Million | $56.85 Million | 0.196x | +54.92% |
| 2004-12-31 | $307.82 Million | $38.98 Million | 0.127x | -2.37% |
| 2003-12-31 | $268.53 Million | $34.83 Million | 0.130x | +0.39% |
| 2002-12-31 | $247.60 Million | $31.98 Million | 0.129x | +67.89% |
| 2001-12-31 | $204.06 Million | $15.70 Million | 0.077x | +183.43% |
| 2000-12-31 | $53.78 Million | $-4.96 Million | -0.092x | -240.18% |
| 1999-12-31 | $38.00 Million | $2.50 Million | 0.066x | +121.08% |
| 1998-12-31 | $31.40 Million | $-9.80 Million | -0.312x | -41.43% |
| 1997-12-31 | $35.80 Million | $-7.90 Million | -0.221x | -27.99% |
| 1996-12-31 | $46.40 Million | $-8.00 Million | -0.172x | +46.43% |
| 1995-12-31 | $17.40 Million | $-5.60 Million | -0.322x | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more